Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications
Introduction: Cross-reactivity to SARS-CoV-2 antigenic peptides has been detected on T-cells from pre-pandemic donors due to recognition of conserved protein fragments within members of the coronavirus's family. Further, preexisting antibodies recognizing SARS-CoV-2 with conserved epitopes in t...
Main Authors: | Marinos C. Dalakas, Kleopatra Bitzogli, Harry Alexopoulos |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.627285/full |
Similar Items
-
Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial
by: Shaukat Ali, et al.
Published: (2020-11-01) -
Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report
by: Hao-Yu Wu, et al.
Published: (2021-09-01) -
Coronavirus host divergence and novel coronavirus (SARS-CoV-2) outbreak
by: Kadir YEŞİLBAĞ, et al.
Published: (2020-04-01) -
New Coronavirus COVID-19 (SARS-CoV-2)
by: O. V. Shamsheva
Published: (2020-03-01) -
What we know and don’t know on SARS-CoV-2 and COVID-19
by: Ignacio Silva-Ayarza, et al.
Published: (2021-05-01)